… impact of open-label design in the context of prostate cancer (… cancer in males, 1 it is not
surprising that prostate cancer (PCa) … is the open-label setting. Hence, the FDA rarely considers …

… options for advanced prostate cancer have increased … Metastatic prostate cancer initially
responds to androgen … referred to as castrate-resistant prostate cancer (CRPC). For patients with …

… prostate cancer, as ≈80% of patients with prostate cancer in … surge, which might stimulate
prostate cancer cells and lead to … been investigated for treating prostate cancer, but many of …

… drugs in castration-resistant prostate cancer suggested that early chemotherapy might
improve the overall outcome of patients with metastatic non-castrate prostate cancer. Thus, we …

… Patients with castration-resistant prostate cancer with no previous chemotherapy were
enrolled in this study. The patients received tasquinimod up to 1 year either at fixed doses of 0.5 …

… We undertook an open-label randomised phase 3 trial in men with metastatic castration-resistant
prostate cancer who had received previous hormone therapy, but whose disease had …

… FSH),2 an important finding because prostate cancer is influenced by several … prostate-specific
antigen (PSA) levels in men with prostate cancer.1, 3 The exposure of the prostate cancer …

… Evidence of single-agent clinical activity was observed with prostate-specific antigen declines
in some patients. Further investigation of AT-101 in prostate cancer is warranted and trials …

Purpose : We compared the endocrinological and biochemical efficacy of abarelix depot, a
gonadotropin-releasing hormone antagonist, with that of a widely used combination of …

… be crucial to interpreting antitumour activity results in gene-by-gene analyses from prostate
cancer PARP inhibitor studies using multi-gene panels, including the TALAPRO-1 study. …